Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.
Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two EGFR mutations in a cohort of 25 salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21 by allele-specific PCR. Here, we present a comprehensive sequencing analysis of the entire critical EGFR tyrosine kinase domain in 65 SGC of the main histopathological types. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs. No additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an adenoid cystic carcinoma have been detected. Other putative predictive markers for EGFR-targeted therapy in SGCs might be relevant and should be investigated.
Dahse
R
R
HELIOS Clinics Erfurt, Institute of Pathology, Nordhauser Street 74, Erfurt 99089, Germany. rdahse@erfurt.helios-kliniken.de
Driemel
O
O
Schwarz
S
S
Dahse
J
J
Kromeyer-Hauschild
K
K
Berndt
A
A
Kosmehl
H
H
D000368:Aged; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000737:chemistry / Q000235:genetics*; D005091:Exons; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017434:Protein Structure, Tertiary; D012468:Salivary Gland Neoplasms / Q000235:genetics*
D066246:ErbB Receptors